Advanced glycation end-products (AGEs): New toxins?;Les produits de glycation avancée (AGE): De nouvelles toxines?

Nephrologie

Volumn 23, Issue 7, 2002, Pages 351-359

  Boulanger, Eric ^a,b   Dequiedt, Ph ^b   Wautier, J L ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Advanced glycation end products; Atherosclerosis; Diabetes mellitus; Dialysis; Oxidation; Renal failure

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CELL RECEPTOR; GLUCOSE; POLYOL;

ARTICLE; AUTOOXIDATION; CATABOLISM; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GLYCATION; HEMODIALYSIS; HOMEOSTASIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MACROPHAGE; MESANGIUM CELL; MESOTHELIUM CELL; OXIDATIVE STRESS; PERITONEAL DIALYSIS; RECEPTOR BINDING; UREMIA;

EID: 0036446435     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Maillard L. Action des acides aminés sur les sucres; formation des mélanoïdes par vole méthodique. CR Acad Sci (Paris) 1912; 154: 66-8.
2. Wautier J. Advanced glycosylation end products or glycotoxins: Underevaluated components of diet? Rev Prat 2001; 51: 1397-9.
3. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-9.
4. Teillet L, Verbeke P, Gouraud S, Bakala H, Borot-Laloi C, Heudes D, Bruneval P, Corman B. Food restriction prevents advanced glycation end product accumulation and retards kidney aging in lean rats. J Am Soc Nephrol 2000; 11: 1488-97.
5. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527-37.
6. Miyata T, Kurokawa K, Van Ypersele de Strihou C. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11: 1744-52.
7. Wautier J, Guillausseau P. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-42.
8. Tsukushi S, Katsuzaki T, Aoyama I, Takayama F, Miyazaki T, Shimokata K, Niwa T. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway. Kidney Int 1999; 55: 1970-6.
9. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
10. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93: 521-8.
11. Makita Z, Vlassara H, Cerami ARB. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-8.
12. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989; 264: 21597-602.
13. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-94.
14. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-9.
15. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-206.
16. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW. Technical note. The serum concentration of the advanced glycation endproduct N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997; 52: 1064-7.
17. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin Alc in diabetes mellitus. N Engl J Med 1976; 295: 417-20.
18. Wolffenbuttel BH, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996; 347: 513-5.
19. Davin JC, Bouts AH, Krediet RT, van der Weel M, Weening RS, Groothoff J, Out TA. IgG glycation and function during continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1997; 12: 310-4.
20. Ligier S, Fortin PR, Newkirk MM. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol 1998; 37: 1307-14.
21. Menini T, Gugliucci A, Stahl AJ. Polyclonal immunoglobulin M: Location of glycation sites. Clin Chim Acta 1992; 213: 23-35.
22. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 1986; 261: 13542-5.
23. Ducrocq R, Bachour H, Belkhodja R, Berriche S, Elion J. Evidence for nonenzymic glycation of antithrombin III in diabetic patients. Clin Chem 1985; 31: 338-9.
24. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
25. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992; 267: 12404-7.
26. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27: 97-108.
27. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-7.
28. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-32.
29. Gilcrease MZ, Hoover RL. Activated human monocytes exhibit receptormediated adhesion to a non-enzymatically glycosylated protein substrate. Diabetologia 1990; 33: 329-33.
30. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-97.
31. Vlassara H, Brownlee M, Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82: 5588-92.
32. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol Med 1995; 1: 634-46.
33. Boulanger E, Wautier M, Wautier J, Boval B, Panis Y, Wernert N, Danze P, Dequiedt P. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-56.
34. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
35. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521-8.
36. Renard C, Chappey O, Wautier MP, Nagashima M, Morser J, Scherrmann JM, Wautier JL. The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats. J Pharmacol Exp Ther 1999; 290: 1458-66.
37. Prevost G, Fajardy I, Fontaine P, Danze PM, Besmond C. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 1999; 26: 343-8.
38. Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L, Vlassara H, Parving HH, Cambien F. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001; 50: 1214-8.
39. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50: 1505-11.
40. Wautier JL, Paton RC, Wautier MP, Pintigny D, Abadie E, Passa P, Caen JP. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med 1981; 305: 237-42.
41. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994; 91: 7742-6.
42. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by Advanced Glycation End-products (AGEs) links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E94.
43. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-506.
44. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
45. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D. RAGE: A novel cellular receptor for advanced glycation end products. Diabetes 1996; 45 (Suppl. 3): S77-80.
46. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21: 905-10.
47. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S 100/calgranulin polypeptides. Cell 1999; 97: 889-901.
48. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6: 643-51.
49. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-61.
50. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
51. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81: 583-7.
52. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.
53. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-68.
54. Stratton IM, Adler Al, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-12.
55. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
56. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-56.
57. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996; 271: C1424-37.
58. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000; 86: E50-4.
59. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
60. Lobo CL, Bernardes RC, Cunha Vaz JG. Alterations of the blood-retinal barrier and retinal thickness in preclinical retinopathy in subjects with type 2 diabetes. Arch Ophthalmol 2000; 118: 1364-9.
61. Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50: 1432-9.
62. Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy Diabetologia 1997; 40: 156-64.
63. Treins C, Giorgetti-Peraldi S, Murdaca J et al. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001; 276: 43836-41.
64. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999; 42: 728-36.
65. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997; 40: 764-9.
66. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-25.
67. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-9.
68. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-66.
69. Krishnamurt U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 1997; 272: 27966-70.
70. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-8.
71. Uesugi N, Sakata N, Horiuchi S, Nagai R, Takeya M, Meng J, Saito T, Takebayashi S. Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am J Kidney Dis 2001; 38: 1016-25.
72. He CJ, Koschinsky T, Buenting C, Vlassara H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 2001; 7: 1513-68.
73. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-8.
74. Pugliese G, Fricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu D, Vlassara H, Liu F, Di Mario U. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB 2001; 15: 2471-9.
75. Vlassara H. Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994; 12: 54-9.
76. Gerdemann A, Lemke HD, Nothdurft A, Heidland A, Munch G, Bahner U, Schinzel R. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 2000; 54: 276-83.
77. Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, van Ypersele de Strihou C, Kurokawa K. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 1998; 53: 416-22.
78. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 1998; 9: 2349-56.
79. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with endstage renal failure. Kidney Int 1997; 51: 1170-81.
80. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 2001; 78: S108-13.
81. Witko-Sarsat V, Friedlander M, Capeillere Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13.
82. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000; 15 (Suppl. 1): 17-24.
83. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001; 16: 999-1008.
84. Randoux C, Gillery P, Georges N, Lavaud S, Chanard J. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Kidney Int 2001; 60: 1571-7.
85. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445-51.
86. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997; 51: 880-7.
87. Nilsson-Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993; 13: 208-13.
88. Linden T, Forsback G, Deppisch R, Henle T, Wieslander A. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998; 18: 290-3.
89. Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 1997; 17: 373-8.
90. Witowski J, Jorres A. Glucose degradation products: Relationship with cell damage. Perit Dial Int 2000; 20 (Suppl. 2): S31-6.
91. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11: 729-39.
92. Dawnay AB, Millar DJ. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997; 17: 52-8.
93. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, Izuhara Y, Saito A, Kurokawa K, Van Ypersele De Strihou C. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 2000; 58: 2518-24.
94. Rashid G, Luzon AA, Kortets Z, Klein O, Zelter E, Bernheim J. The effect of advanced glycation end-products and aminoguanidine on TNFα production by rat peritoneal macrophages. Perit Dial Int 2001; 21: 122-9.
95. Mahiout A, Ehlerding G, Brunkhorst R. Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients. Nephrol Dial Transplant 1996; 11 (Suppl. 5): 2-6.
96. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-6.
97. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-9.
98. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9: 41-5.
99. Yoshida S, Yamada K, Hamaguchi K, Nishimura M, Hatakeyama E, Tsuchida H, Sakamoto K, Kashiwabara H, Yokoyama T, Ikeda K, Horiuchi S. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 1998; 49: 273-80.
100. Rossert J, Ronco P. How to slow the progression of chronic renal insufficiency. Rev Prat 2001; 51: 378-84.
101. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A, Van Ypersele De Strihou C, Kurokawa K. Mechanism of the inhibitory effect of OPB9195. J Am Soc Nephrol 2000; 11: 1719-25.
102. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 2001; 50: 1636-42.
103. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001;12: 2098-107.
104. Abdel-Rahman E, Bolton W. Pimagedine: A novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002; 11: 565-74.
105. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-4.
106. Schwedler SB, Verbeke P, Bakala H, Weiss MF, Vilar J, Depreux P, Fourmaintraux E, Striker LJ, Striker GE. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. Diabetes Obes Metab 2001; 3: 230-9.
107. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4.